UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4.63 Million Stock Position in Geron Co. (NASDAQ:GERN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Geron Co. (NASDAQ:GERN) by 13.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,020,743 shares of the biopharmaceutical company’s stock after acquiring an additional 118,688 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Geron were worth $4,634,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Darwin Global Management Ltd. purchased a new position in Geron in the second quarter valued at approximately $106,185,000. Farallon Capital Management LLC boosted its position in shares of Geron by 124.6% during the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock valued at $71,389,000 after acquiring an additional 9,342,000 shares during the last quarter. First Turn Management LLC purchased a new position in Geron in the 3rd quarter worth approximately $14,187,000. abrdn plc purchased a new position in Geron in the third quarter worth $6,752,000. Finally, TD Asset Management Inc increased its position in shares of Geron by 403.0% during the 2nd quarter. TD Asset Management Inc now owns 1,201,200 shares of the biopharmaceutical company’s stock valued at $5,093,000 after purchasing an additional 962,400 shares during the last quarter. 73.71% of the stock is owned by institutional investors.

Geron Stock Down 0.3 %

GERN stock opened at $3.98 on Thursday. The firm’s fifty day moving average is $4.08 and its 200 day moving average is $4.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron Co. has a one year low of $1.64 and a one year high of $5.34. The firm has a market cap of $2.41 billion, a PE ratio of -12.44 and a beta of 0.51.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. The firm had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm’s revenue for the quarter was up 17138.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.08) earnings per share. On average, research analysts forecast that Geron Co. will post -0.25 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Leerink Partners started coverage on Geron in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price for the company. Barclays raised shares of Geron to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Geron in a research report on Tuesday. Scotiabank initiated coverage on shares of Geron in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target on the stock. Finally, Leerink Partnrs upgraded Geron to a “strong-buy” rating in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Geron has a consensus rating of “Moderate Buy” and an average target price of $7.15.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.